Table 2.
Response to first‐line chemotherapy in the included patients
| BRAF mutation (n = 28) | EGFR mutation (n = 151) | KRAS mutation (n = 130) | P valuea | P valueb | |
|---|---|---|---|---|---|
| CR | 0 | 0 | 0 | ||
| PR | 8 | 51 | 32 | ||
| SD | 14 | 70 | 61 | ||
| PD | 6 | 30 | 37 | ||
| ORR | 8 (28.6%) | 51 (33.8%) | 32 (24.6%) | 0.591 | 0.662 |
| DCR | 22 (78.6%) | 121 (80.1%) | 93 (71.5%) | 0.850 | 0.448 |
CR, complete response; PR, partial response; SD, stable disease; PD, progression disease; ORR, objective response rate; DCR, disease control rate.
a
P value refers to the comparison of BRAF versus epidermal growth factor receptor mutation.
b
P value refers to the comparison of BRAF versus KRAS mutation.